Anti-Cardiolipin Antibody (ACLA)

Coagulation

---

Description

The Anti-Cardiolipin antibody test (IgG and IgM) is performed as part of the Lupus screen to detect antiphospholipid antibodies.

Antiphospholipid antibodies are a group of antibodies which include lupus anticoagulant, anticardiolipin antibodies (IgG or IgM) and antiβ2-glycoprotein-1 antibodies (IgG) which are associated with thrombosis and pregnancy loss/morbidity. Antiphospholipid syndrome is characterised by persistent positivity of these antibodies together with the clinical symptoms.

Cardiolipin is a component of most human cells. Binding of antiphospholipid antibodies (antibodies reactive to proteins in complex with negatively charged phospholipids) to anticardiolipin also requires the presence of β2GP1 as a cofactor.

Here in Sheffield Laboratory Medicine Anti-Cardiolipin antibodies are measured by automated immunoassays using chemiluminescent technology.

---

Sample Type

Plain clotted x 1

---

Reference Range

IgG and IgM reference ranges indicated on report.

---

Turnaround Time

Within 2 weeks

---

Testing Frequency

Weekly

---

External Notes

The accuracy of all coagulation tests is greatly influenced by pre analytical variables. It is essential that sample quality is given the highest of priorities. Samples which fail to meet quality criteria including age of sample, specimen fill (>90%), haemolysed, clotted or activated samples will be rejected and a repeat sample requested. Included in the Lupus screen.

---

Patient Preparation

No Special Requirements.

---

References

Guidelines on the investigation and management of antiphospholipid syndrome. BJH, 2012,157,47-58.

---

See Also

Lupus Anticoagulant Antibody Screen
Dilute Russell's Viper Venom Time ( DRVVT )
Anti-Beta 2 Glycoprotein1 Antibody

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.